People with TB Archives – Page 3 of 7

An Activist’s Guide to Shorter Treatment for Drug-Sensitive Tuberculosis

October 26, 2021
Dorrit Walsh

After a decades-long wait, shorter treatment for drug-sensitive tuberculosis (TB) for adults and children is finally possible. Two landmark clinical trials (S31/A5349 and SHINE) have demonstrated that adults, adolescents, and some children can be cured of TB in as little as four months.

Statement from TAG’s TB Project on Today’s WHO Global TB Report

October 14, 2021
Dorrit Walsh

Today's Global TB Report from WHO confirms our worst expectations for how COVID-19 has set back the global TB response. The pandemic has reversed an entire generation of progress. The first year-on-year increase in TB deaths since 2005 is devastating.

The TB Research Engine That Could: Sustaining the Success of TBTC Research in Turbulent Times

May 10, 2021
Dorrit Walsh

This publication explores the critical role the Tuberculosis Trials Consortium holds in increasing the store of knowledge about TB cures and other tools, demonstrates the implications that a lack of funding will have across the TB pipeline, and offers recommendations to ensure the gains made in TB research are not lost.

Landmark TB Trials Results Published in New England Journal of Medicine

May 6, 2021
Dorrit Walsh

Today the New England Journal of Medicine published results of a landmark phase III clinical trial that found a 4-month regimen containing rifapentine and moxifloxacin performed as well as the six-month standard regimen in curing drug-susceptible pulmonary TB.

Community Movements Across Africa, Asia and South America Celebrate Roll-Out of Short-Course, Patient-Friendly TB Preventive Therapy

February 16, 2021
Dorrit Walsh

Advocates and affected communities working towards the global scale-up of short-course TB preventive therapy (TPT) hail the recent announcement of the launch of decently priced, patient-friendly fixed-dose combinations (FDC) of 3HP in five high burden HIV and TB countries.

Finally—A New Four-Month Treatment for Drug-Susceptible TB!

October 21, 2020
Dorrit Walsh

Treatment Action Group (TAG) and the Community Research Advisors Group (CRAG) welcome the news of a safe and effective regimen for shortening tuberculosis (TB) treatment to just four months.

Por fin un nuevo tratamiento de cuatro meses para la tuberculosis sensible a fármacos

October 21, 2020
Dorrit Walsh

El Grupo de Acción para el Tratamiento (TAG, por sus siglas en inglés) y el Grupo de Asesores Comunitarios de Investigación (CRAG, por sus siglas en inglés) se congratulan ante la noticia de un régimen seguro y eficaz capaz de acortar el tratamiento de la tuberculosis (TB) a sólo cuatro meses.

Advancing Access through Market Interventions: Lessons Learned from the GeneXpert Tuberculosis Test Buy-Down

September 21, 2020
Dorrit Walsh

This policy brief examines lessons learned from the Xpert MTB/RIF TB test buy-down and provides recommendations and pro-access conditions that should be applied to R&D funding, buy-down, and other market intervention agreements for COVID-19 diagnostics.

Public Investment in Bedaquiline Up to Five-Fold That of Johnson & Johnson

September 18, 2020
Dorrit Walsh

Treatment Action Group’s independent, peer-reviewed analysis found public investment in the development of bedaquiline was up to five times that of Johnson and Johnson. This finding appears in the new PLOS ONE article, “Public Investments in the Clinical Development of Bedaquiline.”

Treatment Action Group Condemns Reported Bullying, Harassment, and Racism at Stop TB Partnership

September 13, 2020
Dorrit Walsh

Treatment Action Group (TAG) strongly condemns alleged bullying, harassment, and racism directed toward staff and contractors of the Stop TB Partnership, as reported by The New York Times. As a long-term and current grantee of the Stop TB Partnership, we stand in solidarity with current and former staff and contractors whom this harassment and racism has affected.